Date: 2015-12-14
Type of information: R&D agreement
Compound: monoclonal antibodies
Company: Sanofi (France) MAB Discovery (Germany)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism: monoclonal antibody
Disease:
Details: * On December 14, 2015, Sanofi and MAB Discovery GmbH announced that they have entered into a research and license agreement in the field of monoclonal antibodies. Within the scope of this collaboration, MAB Discovery will develop therapeutic antibodies for selected targets of Sanofi and thus support Sanofi in the development of antibody-based therapies. Sanofi will in return receive high-quality antibodies with the aim of identifying active substances for a number of diseases that are difficult to treat. MAB Discovery was founded in Munich, Germany in October 2010. The team represents a group of scientists out of Roche Biologicals R&D with extensive experience in developing biologically based therapeutics. The company uses its technology platform for the discovery of antibodies in vivo, which are based on natural immune responses in rabbits. Subsequently,MAB Discovery employs state-of-the-art technology for the cloning of antibodies directly from B-cells.
Financial terms: Sanofi and MAB Discovery have agreed on a fee for the research activities. When specific milestones are achieved, the agreement provides for further performance-related payments to MAB Discovery. Financial details of the agreement were not disclosed.
Latest news:
